Overall Survival as a Driver of 1L EGFRm NSCLC Treatment Selection

Weighing Overall Survival in Treatment Decisions

Main Discussion Topics:

• The relative importance of overall survival as an end point in clinical decision-making
• Additional factors beyond survival data that influence treatment selection
• Considerations regarding treatment sequencing and patient crossover between therapies

Key Points for Physicians:

• Overall survival is important but not the sole determining factor in treatment decisions
• Patient factors including age, disease burden, performance status, and social situation must be considered
• Treatment sequencing (eg, when to use amivantamab—first-line or later) requires careful consideration

Notable Insights:

The panelists note that only 1% to 2% of patients in the osimertinib arm of MARIPOSA crossed over to receive amivantamab later, raising questions about optimal sequencing strategies.

Clinical Significance:

Although overall survival data are compelling, treatment decisions require balancing efficacy with patient-specific factors and considerations of toxicity profiles and quality of life.